Bicycle Therapeutics PLC

NASDAQ:BCYCUnited States

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.

Contact Information

Headquarters

Blocks A & B, Portway Building, Granta PCAMBRIDGE, United Kingdom CB21 6GS

Phone

122-326-1503

Fax

---

Executives

Non-Executive Chairman of the Board

Pierre Legault

Chief Executive Officer, Executive Director

Kevin Lee

Chief Financial Officer, Principal Financial Officer

Alethia Young

Chief Operating Officer

Alistair Milnes

Chief Technology Officer

Michael Skynner